Cargando…
Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence
BACKGROUND: SARS‐CoV‐2 infection triggers different auto‐antibodies, including anti‐apolipoprotein A‐1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID‐19 and the impact of AAA1 on the inflammatory response and s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348059/ https://www.ncbi.nlm.nih.gov/pubmed/35598178 http://dx.doi.org/10.1111/eci.13818 |
_version_ | 1784761899284430848 |
---|---|
author | L’Huillier, Arnaud G. Pagano, Sabrina Baggio, Stephanie Meyer, Benjamin Andrey, Diego O. Nehme, Mayssam Guessous, Idris Eberhardt, Christiane S. Huttner, Angela Posfay‐Barbe, Klara M. Yerly, Sabine Siegrist, Claire‐Anne Kaiser, Laurent Vuilleumier, Nicolas |
author_facet | L’Huillier, Arnaud G. Pagano, Sabrina Baggio, Stephanie Meyer, Benjamin Andrey, Diego O. Nehme, Mayssam Guessous, Idris Eberhardt, Christiane S. Huttner, Angela Posfay‐Barbe, Klara M. Yerly, Sabine Siegrist, Claire‐Anne Kaiser, Laurent Vuilleumier, Nicolas |
author_sort | L’Huillier, Arnaud G. |
collection | PubMed |
description | BACKGROUND: SARS‐CoV‐2 infection triggers different auto‐antibodies, including anti‐apolipoprotein A‐1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID‐19 and the impact of AAA1 on the inflammatory response and symptoms persistence. METHODS: All serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID‐19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient‐reported COVID‐19 symptoms persistence at 12 months. Interferon (IFN)‐α and‐γ production by AAA1‐stimulated human monocyte‐derived macrophages (HMDM) was assessed in vitro. RESULTS: AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID‐19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti‐SARS‐COV2 serologies decreased, but remained significant. From the 3(rd) month on, AAA1 levels predicted persistent respiratory symptoms (area under the curves 0.72‐0.74; p < 0.001), independently of disease severity, age and gender (adjusted odds ratios 4.81–4.94; p = 0.02), while anti‐SARS‐CoV‐2 serologies did not. AAA1 increased IFN‐α production by HMDMs (p = 0.03), without affecting the IFN‐γ response. CONCLUSION: COVID‐19 induces a marked though transient AAA1 response, independently predicting one‐year persistence of respiratory symptoms. By increasing IFN‐α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID‐19 risk stratification remains to be determined. |
format | Online Article Text |
id | pubmed-9348059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93480592022-08-04 Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence L’Huillier, Arnaud G. Pagano, Sabrina Baggio, Stephanie Meyer, Benjamin Andrey, Diego O. Nehme, Mayssam Guessous, Idris Eberhardt, Christiane S. Huttner, Angela Posfay‐Barbe, Klara M. Yerly, Sabine Siegrist, Claire‐Anne Kaiser, Laurent Vuilleumier, Nicolas Eur J Clin Invest Original Articles BACKGROUND: SARS‐CoV‐2 infection triggers different auto‐antibodies, including anti‐apolipoprotein A‐1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID‐19 and the impact of AAA1 on the inflammatory response and symptoms persistence. METHODS: All serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID‐19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient‐reported COVID‐19 symptoms persistence at 12 months. Interferon (IFN)‐α and‐γ production by AAA1‐stimulated human monocyte‐derived macrophages (HMDM) was assessed in vitro. RESULTS: AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID‐19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti‐SARS‐COV2 serologies decreased, but remained significant. From the 3(rd) month on, AAA1 levels predicted persistent respiratory symptoms (area under the curves 0.72‐0.74; p < 0.001), independently of disease severity, age and gender (adjusted odds ratios 4.81–4.94; p = 0.02), while anti‐SARS‐CoV‐2 serologies did not. AAA1 increased IFN‐α production by HMDMs (p = 0.03), without affecting the IFN‐γ response. CONCLUSION: COVID‐19 induces a marked though transient AAA1 response, independently predicting one‐year persistence of respiratory symptoms. By increasing IFN‐α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID‐19 risk stratification remains to be determined. John Wiley and Sons Inc. 2022-06-02 /pmc/articles/PMC9348059/ /pubmed/35598178 http://dx.doi.org/10.1111/eci.13818 Text en © 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles L’Huillier, Arnaud G. Pagano, Sabrina Baggio, Stephanie Meyer, Benjamin Andrey, Diego O. Nehme, Mayssam Guessous, Idris Eberhardt, Christiane S. Huttner, Angela Posfay‐Barbe, Klara M. Yerly, Sabine Siegrist, Claire‐Anne Kaiser, Laurent Vuilleumier, Nicolas Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title | Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title_full | Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title_fullStr | Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title_full_unstemmed | Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title_short | Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence |
title_sort | autoantibodies against apolipoprotein a‐1 after covid‐19 predict symptoms persistence |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348059/ https://www.ncbi.nlm.nih.gov/pubmed/35598178 http://dx.doi.org/10.1111/eci.13818 |
work_keys_str_mv | AT lhuillierarnaudg autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT paganosabrina autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT baggiostephanie autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT meyerbenjamin autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT andreydiegoo autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT nehmemayssam autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT guessousidris autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT eberhardtchristianes autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT huttnerangela autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT posfaybarbeklaram autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT yerlysabine autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT siegristclaireanne autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT kaiserlaurent autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence AT vuilleumiernicolas autoantibodiesagainstapolipoproteina1aftercovid19predictsymptomspersistence |